Combined marker and detection kit for diagnosing Parkinson's disease

A technology of Parkinson's disease and reagent kit, which is applied in the field of analytical chemistry, clinical medicine and medicine, can solve the problems of limited accuracy and sensitivity, lack of effective biomarkers, etc., and achieve the effect of low cost and high stability

Active Publication Date: 2020-04-17
FIRST AFFILIATED HOSPITAL OF DALIAN MEDICAL UNIV
View PDF8 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The purpose of the present invention is to provide a combination of small molecule metabolites to assist the clinical diagnosis of Parkinson's disease, and to provide a combination of small molecule metabolites that can be used to detect the above-mentioned Combinatorial Small Molecule Metabolite Detection Methods

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined marker and detection kit for diagnosing Parkinson's disease
  • Combined marker and detection kit for diagnosing Parkinson's disease
  • Combined marker and detection kit for diagnosing Parkinson's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] 1. Collection of Plasma Samples

[0030] Collected 122 patients with Parkinson's disease (PD), 94 normal subjects (Ctrl) and 68 patients with non-PD neurological diseases (NDC, including 27 cases of cerebrovascular disease, 9 cases of epilepsy, 9 cases of peripheral vertigo, 8 cases of peripheral neuropathy, 8 sleep disturbances, 5 syncope, and 2 myasthenia gravis). Before the plasma collection, the experiment needs to obtain the approval of the institutional ethics committee and the informed consent of all subjects. All subjects were fasted for more than 8 hours, and blood was collected the next morning. The collected blood samples were left to stand for 30 minutes, centrifuged at 3000rpm / min for 5 minutes, and plasma was collected and stored in a -80°C refrigerator for later use.

[0031] 2. Analysis method

[0032] 2.1 Pretreatment of plasma samples

[0033] Table 1. Internal standards and their concentrations in the extract

[0034]

[0035] Take out the plas...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to view more

Abstract

The invention relates to new application of small molecular metabolites caffeine, creatinine, eicosamide, phenylacetylglutamine, decanoic acid and indolelactic acid in a plasma sample as combined markers in preparation of a kit for diagnosing Parkinson's disease patients in subjects. The invention also relates to the kit for detecting the Parkinson's disease patients in the subjects, and the kit is used for calculating the variables of the combined markers based on a binary logistic regression equation by detecting the respective relative concentrations of the combined markers in the plasma from the subjects, and judging whether the subjects suffer from Parkinson's disease or not based on determined intercept values. The kit can realize high-sensitivity detection of several metabolites involved in the invention, and has the characteristics of low detection cost and good repeatability. The combined use of the small molecule metabolites can be used for assisting the clinical diagnosis ofthe Parkinson's disease, and has higher development and application values.

Description

technical field [0001] The invention relates to the application of a new small molecule joint marker in the diagnosis of Parkinson's disease, and relates to a detection kit and method for detecting Parkinson's disease in subjects, belonging to the fields of analytical chemistry, clinical medicine and medicine. Background technique [0002] Parkinson's disease (PD) is the second most common neurodegenerative disease, mostly in the elderly. With the aging of the population, the incidence of PD is increasing. At present, the clinical diagnosis of PD is mainly based on medical history, clinical symptoms and response to levodopa treatment, and there is a high rate of missed diagnosis and misdiagnosis. Because the pathogenesis of PD is still unclear, traditional drug treatment can only temporarily relieve or relieve symptoms, but cannot effectively prevent or reverse the progress of PD, and long-term medication will cause many complications [Reference 1: Oxenkrug G, Van dHM, Roe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N30/02G01N30/06G01N30/34G01N30/36G01N30/72G01N30/86G01N30/88
CPCG01N30/02G01N30/06G01N30/34G01N30/36G01N30/7266G01N30/8686G01N30/88G01N2030/027G01N2030/8822
Inventor 乐卫东邵亚平李天白许国旺
Owner FIRST AFFILIATED HOSPITAL OF DALIAN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap